The global Biosimilars market estimated at US$19.4 Billion in the year 2021 is now projected to grow at a CAGR of 20.37% and reach US$59.1 Billion by 2027.
The research report provides a comprehensive review of market trends (Technology, Product and Application analysis), market growth drivers, PEST Analysis (Political, Economic, Social and Technological Analysis) Market growth inhibitors, and strategic industry activities and SWOT Analysis of key players in the market. The report provides market estimates and forecast for geographic markets such as the North America (United States, Canada, Mexico and Rest of North America), South America (Brazil, Argentina Chile Colombia Peru Venezuela Ecuador and Rest of South America), Europe (Germany, France, U.K., Russia, Italy, Spain, Sweden, Netherlands, Poland, Austria, Belgium, Finland, Norway, Switzerland, Denmark, Czech Republic, Portugal and Rest of Europe), Asia-Pacific (China, Japan, South Korea, Taiwan, India, Australia, Indonesia, Philippines, Malaysia and Rest of Asia-Pacific), Middle East (Iran, Turkey, Kuwait, UAE, Israel, Oman, Bahrain, Saudi Arabia, Qatar, Egypt and Rest of Middle East) & Africa.
Key players profiled in the report include Allergan Plc; Amgen Inc.; Biocon Ltd.; Biopartners GmbH; Boehringer Ingelheim International GmbH; Celltrion Inc.; Dr. Reddy`s Laboratories Ltd.; Eli Lilly and Company; Fresenius Kabi; Intas Pharmaceuticals Ltd.; Mylan NV; Pfizer Inc.; Samsung Bioepis Co. Ltd.; Sandoz International GmbH; STADA Arzneimittel AG; Teva Pharmaceutical Industries Ltd. among others.
Research Methodology
